Trillium Announces Pricing of US$101,700,000 Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares
23 janv. 2020 08h15 HE
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
Trillium Announces Proposed Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares
22 janv. 2020 16h01 HE
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., Jan. 22, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
Trillium Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
16 janv. 2020 08h00 HE
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., Jan. 16, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 CD47 Programs
07 janv. 2020 08h30 HE
|
Trillium Therapeutics Inc.
Intravenous TTI-621 dose escalation under initial dose limiting toxicity (DLT) criteria now completed – confirms TTI-621 monotherapy activity (including complete responses) in hematologic malignancies...
Trillium Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
14 nov. 2019 07h00 HE
|
Trillium Therapeutics Inc.
TORONTO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for...
Trillium Therapeutics to Report Preclinical Data on Its STING Program at the SITC 34th Annual Meeting
06 nov. 2019 07h00 HE
|
Trillium Therapeutics Inc.
TORONTO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today...
Trillium Therapeutics Announces Corporate Restructuring and Provides CD47 Program Update
22 oct. 2019 09h00 HE
|
Trillium Therapeutics Inc.
TORONTO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Trillium, "the company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
Trillium Granted 180-Day Extension by NASDAQ to Regain Compliance With Minimum Bid Price Rule
08 oct. 2019 07h00 HE
|
Trillium Therapeutics Inc.
TORONTO, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today...
Trillium Therapeutics Appoints Jan Skvarka as President and Chief Executive Officer
25 sept. 2019 07h00 HE
|
Trillium Therapeutics Inc.
TORONTO, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
Trillium Therapeutics To Present At Investor Conference
05 sept. 2019 07h00 HE
|
Trillium Therapeutics Inc.
TORONTO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...